Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New tests could help spot hidden blood disorder in seniors

NCT ID NCT01648556

First seen Mar 16, 2026 · Last updated Jun 19, 2026 · Updated 9 times

Summary

This study followed 37 adults over age 60 with unexplained low platelet counts to see if certain tests could predict immune thrombocytopenic purpura (ITP). Participants had blood tests, bone marrow biopsies, and a short course of the steroid prednisone. The goal was to find which tests best point to ITP, helping doctors avoid unnecessary procedures and start the right treatment sooner.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIC PURPURA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • CHU Amiens

    Amiens, 80000, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

prednisone

What this could lead to

If successful, this could help doctors better diagnose immune thrombocytopenia in older adults, leading to more targeted treatment.

What could go wrong

This is a small, completed study with only 37 participants. The results may not apply to all patients, and the tests studied might not be reliable enough for routine use.

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura thrombocytopenic purpura

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.